SCHEMBL4877209

SCHEMBL4877209

Cn1cccc1-c1ccc2cc(-c3c(-c4ccccc4)c4sc(C(=O)O)cc4n3Cc3ccncc3)ccc2n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
TSHR P16473 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PPARG P37231 5/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
BRD4 O60885 1/20 0.32
NAMPT P43490 2/20 0.31
TBXAS1 P24557 1/20 0.31
ALOX15 P16050 1/20 0.31
PDE10A Q9Y233 1/20 0.31
PKN1 Q16512 1/20 0.31
PKN2 Q16513 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
ALOX5AP P20292 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4877200 0.87 KDM4E (0.33) KDM4EALDH1A1LMNAMAPTTSHR
SCHEMBL4879018 0.86 MAPK14 (0.37) KDM4EALDH1A1MEN1KMT2AALOX5AP
SCHEMBL4875185 0.86 PPARG (0.40) KDM4EALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL4868096 0.86 KDM4E (0.39) KDM4EALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL4872488 0.85 KCNH2 (0.35) TSHRPPARGMEN1KMT2ANAMPT
SCHEMBL4866909 0.85 ALOX5AP (0.35) PPARGMEN1KMT2APDE10AHDAC1
SCHEMBL4873278 0.85 GRIN1 (0.37) ALDH1A1HSD17B10PPARGMEN1KMT2A
SCHEMBL4878284 0.85 MAOA (0.40) KDM4EALDH1A1LMNASMN1; SMN2PPARG
SCHEMBL4867600 0.84 DHODH (0.38) ALDH1A1PPARGMEN1KMT2APDE10A
SCHEMBL4872023 0.83 CYP17A1 (0.36) KDM4EALDH1A1SMN1; SMN2PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051384-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 KDM4E 3075/4885ALDH1A1 1357/4885LMNA 3337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.